BioNTech received
U.S. FDA approval for their COMIRNATY® vaccine to be used in adults 65+ and high-risk individuals 5-64 years old. However, clearance for administration to children under 5 years old has been withdrawn. The company suffered a setback in the
U.K. Court of Appeal where
Moderna and Freshfields won against them and
Pfizer. Despite this, updates received approval, covering older adults and high-risk individuals against the LP.8.1 variant. Disputes with
CureVac and
GSK have been settled and an
11 billion dollar deal has been agreed with BMS for a Cancer project. BioNTech anticipates
job cuts as it aligns its strategic focus. It's also set to acquire
CureVac in a $1.25 billion all-stock deal, ending a lingering mRNA patent dispute. The agreement has propelled BioNTech into mRNA oncology research. The company is withdrawing from
cell therapy manufacturing in Maryland which is expected to result in lay-offs. This comes as
revenue decline was projected for 2025.
BIONTECH News Analytics from Sat, 28 Dec 2024 08:00:00 GMT to Sat, 30 Aug 2025 23:31:48 GMT -
Rating -2
- Innovation 8
- Information 7
- Rumor -3
